



BEST AVAILABLE COPY

GAC 1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. 107.823.166)

In re Application of:

LEVEUGLE et al.

Serial No. 09/332,866

Filed: June 15, 1999

For: THERAPEUTIC COMPOSITION AND METHOD)  
FOR TREATMENT OF PROSTATE CANCER )

) Examiner: Davis M.

) Art Unit: 1642

RECEIVED

MAR 15 2001

TECH CENTER 1600/2900

\*\*\*\*\*

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an enveloped addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

March 5, 2001

Date of Signature and of Mail Deposit

Diana Havens

Diana Havens

\*\*\*\*\*

Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:


Enclosed for filing are the following documents:

1. Information Disclosure Statement;
2. PTO form 1449 and copies of 141 (one hundred forty-one) references;
3. Return postcard.

Transmittal Letter  
09,332,866  
March 5, 2001

No fees are believed to be due with this communication; however, please charge any additional fees or credit any overpayment associated with this matter to our Deposit Account No. 08-0219.

Respectfully submitted,  
HALE AND DORR LLP



Nancy Chiu, Ph.D.  
Registration No. 43,545  
Agent for Applicants

RECEIVED

MAR 15 2001

TECH CENTER 1600/2900

Date: March 5, 2001  
60 State Street  
Boston, MA 02109  
(617) 526-6000  
(617) 526-5000 (fax)

Title: Therapeutic Composition and Method for Treatment of Prostate Cancer

Serial/Patent No. 091332,866 Applicant Leveque et al.

In the above matter, the following have been received by the US Patent and Trademark Office on the date stamped hereon.

- |   |   |
|---|---|
| <input type="checkbox"/> Express Mail Label No. _____   | <input checked="" type="checkbox"/> Certificate of Mailing under 37 CFR 1.8(a)                                    |
| <input type="checkbox"/> Application incl. _____ pages ( <input type="checkbox"/> Design )      | <input type="checkbox"/> Response to Office Action/Restriction Req.   |
| _____ pp. of specification  | <input type="checkbox"/> Petition for _____ month extension of time   |
| _____ pp. of claims (# of claims - _____)   | <input type="checkbox"/> Assignment and Cover Sheet   |
| _____ pp. of abstract   | <input type="checkbox"/> Amendment ( <input type="checkbox"/> Preliminary; <input type="checkbox"/> After Final ) |
| _____ sheets of drawings; Figs. _____   | <input type="checkbox"/> Notice of Appeal   |
| <input type="checkbox"/> formal <input type="checkbox"/> informal                               | <input type="checkbox"/> Appellant's Brief (triplicate) ( <input type="checkbox"/> Reply Brief )                  |
| <input type="checkbox"/> Provisional Application Cover Sheet                                    | <input type="checkbox"/> Letter to Chief Draftsperson   |
| <input type="checkbox"/> Declaration / Power of Attorney ( <input type="checkbox"/> Unsigned )  | <input type="checkbox"/> Issue Fee / <input type="checkbox"/> Maintenance Fee Transmittal                         |
| <input type="checkbox"/> Verified Statement Claiming Small Entity Status                        | <input type="checkbox"/> Sequence listing; <input type="checkbox"/> Diskette                                      |
| <input type="checkbox"/> Copy of Notice to File Missing Parts <input type="checkbox"/> Response | <input type="checkbox"/> Transmittal Letter   |
| <input type="checkbox"/> Request for filing CPA; 37 CFR 1.53(d)                                 | <input type="checkbox"/> Check for \$ _____; check # _____  |
| <input checked="" type="checkbox"/> IDS, PTO-1449, and <u>14</u> references (Supp. _____)       | <input checked="" type="checkbox"/> Deposit Account Authorization \$ <u>180.</u>                                  |

☐ other: \_\_\_\_\_

☐ other: \_\_\_\_\_

Mailing Date: March 5, 2001 Docket No. 107823.166 Atty/paralegal/secy: UC/DH

Title: Therapeutic Composition and Method for Treatment of Prostate Cancer

Serial/Patent No. 091332,866 Applicant Leveque et al.

In the above matter, the following have been received by the US Patent and Trademark Office on the date stamped hereon.


- |   |   |
|---|---|
| <input type="checkbox"/> Express Mail Label No. _____   | <input checked="" type="checkbox"/> Certificate of Mailing under 37 CFR 1.8(a)                                    |
| <input type="checkbox"/> Application incl. _____ pages ( <input type="checkbox"/> Design )      | <input type="checkbox"/> Response to Office Action/Restriction Req.   |
| _____ pp. of specification  | <input type="checkbox"/> Petition for _____ month extension of time   |
| _____ pp. of claims (# of claims - _____)   | <input type="checkbox"/> Assignment and Cover Sheet   |
| _____ pp. of abstract   | <input type="checkbox"/> Amendment ( <input type="checkbox"/> Preliminary; <input type="checkbox"/> After Final ) |
| _____ sheets of drawings; Figs. _____   | <input type="checkbox"/> Notice of Appeal   |
| <input type="checkbox"/> formal <input type="checkbox"/> informal                               | <input type="checkbox"/> Appellant's Brief (triplicate) ( <input type="checkbox"/> Reply Brief )                  |
| <input type="checkbox"/> Provisional Application Cover Sheet                                    | <input type="checkbox"/> Letter to Chief Draftsperson   |
| <input type="checkbox"/> Declaration / Power of Attorney ( <input type="checkbox"/> Unsigned )  | <input type="checkbox"/> Issue Fee / <input type="checkbox"/> Maintenance Fee Transmittal                         |
| <input type="checkbox"/> Verified Statement Claiming Small Entity Status                        | <input type="checkbox"/> Sequence listing; <input type="checkbox"/> Diskette                                      |
| <input type="checkbox"/> Copy of Notice to File Missing Parts <input type="checkbox"/> Response | <input type="checkbox"/> Transmittal Letter   |
| <input type="checkbox"/> Request for filing CPA; 37 CFR 1.53(d)                                 | <input type="checkbox"/> Check for \$ _____; check # _____  |
| <input checked="" type="checkbox"/> IDS, PTO-1449, and <u>14</u> references (Supp. _____)       | <input checked="" type="checkbox"/> Deposit Account Authorization \$ <u>180.</u>                                  |

☐ other: \_\_\_\_\_

☐ other: \_\_\_\_\_

Mailing Date: March 5, 2001 Docket No. 107823.166 Atty/paralegal/secy: UC/DH

RECEIVED  
OCT 11 2001  
TECH CENTER 1600/2900





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. 107.823.166)

#14  
y/e  
3/24/01

In re Application of:  
LEVEUGLE et al.

) Examiner: Davis M.

Serial No. 09/332,866

) Art Unit: 1642

Filed: June 15, 1999

For: THERAPEUTIC COMPOSITION AND METHOD)  
FOR TREATMENT OF PROSTATE CANCER )

RECEIVED

MAR 15 2001

TECH CENTER 1600/2900

\*\*\*\*\*

**CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an enveloped addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on the date indicated below.

March 5, 2001

Date of Signature and of Mail Deposit

Diana Havens

Diana Havens

\*\*\*\*\*

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Applicants submit herewith the references listed on the attached form PTO 1449, copies of which are enclosed. The submission of this statement is not a representation that a search has been made, or that no better art exists. This submission is also not an admission that any of the cited references is, or is considered to be, material to patentability or that any of the cited references constitutes prior art to the invention.

This statement is being filed under 37 C.F.R. §1.97(c)(2) after a first Office Action on the merits, but before the receipt of a Final Office Action or a Notice of Allowance. Please charge our Deposit Account No. 08-0219 the required fee of \$180.00 pursuant to 37 C.F.R. §1.17(p).

Applicant reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents do not constitute prior art under United States law, Applicant reserves the right to present to the Officer the relevant facts and law regarding the appropriate status of such documents.

It is respectfully requested that the Examiner initial and return copies of the enclosed form PTO-1449 with the next Patent Office communication.



Information Disclosure Statement  
Page 2 of 2  
09/332,866

RECEIVED

MAR 15 2001

TECH CENTER 1600/2900

No additional fees are believed to be due in connection with this submission. However, please apply any additional charges, or credit any overpayment, to our Deposit Account No. 08-0219.


Respectfully submitted,  
HALE AND DORR LLP

Date: March 5, 2001

Nancy Chiu

Nancy Chiu, Ph.D.  
Registration No. 43,545  
Agent for Applicants

60 State Street  
Boston, MA 02109  
(617) 526-6000  
(617) 526-5000 (fax)



Subt. For, PTO-1449

# INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Sheet

1

OF

8

Docket Number  
107.823.166

Application Number  
09/332,866

Applicant  
Leveugle et al.

Filing Date  
June 15, 1999

Group Art Unit  
1642

## U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,865,689	02/11/1975	Goldenberg	195	1.7	
	4,331,647	05/25/1982	Goldenberg	424	1	
	5,053,224	10/01/1991	Koprowski et al.	424	85.8	
	5,165,922	11/24/1992	Hellstrom et al.	424	85.8	

## Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 234 122 A2	09/02/1987	EP				
	0 308 208 A1	03/22/1989	EP				
	WO 89/05140	06/15/1989	PCT				
	WO 88/03954	06/02/1988	PCT				
	WO 87/00053	01/15/1987	PCT				

## Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

	Abbas AK et al., "Antigen presentation by B lymphocytes," <i>Antigen Presenting Cells: Diversity, Differentiation, and Regulation</i> 269-279 (1988)
	Adams S et al., "Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings," <i>Eur J Nucl Med.</i> 25(9):1277-83 (1998)
	Alzona M et al., "IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells," <i>J Immunol.</i> 154(1):9-16 (1995)
	American Cancer Society, "Cancer Facts and Figures," Atlanta, GA: American Cancer Society (1995)
	Andersson K et al., "Modulation of antigen-antibody complexations by immunoglobulins," <i>Scand J Immunol.</i> 42(4):407-17 (1995)
	Bachmann MF et al., "Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen," <i>Eur J Immunol.</i> 24(10):2567-70 (1994)
	Barnd DL et al., "Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells," <i>Proc Natl Acad Sci U S A.</i> 86(18):7159-63 (1989)
	Bartoloni C et al., "Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients," <i>Oncology</i> 50(1):27-34 (1993)
	Bast RC Jr. et al., "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer," <i>New England J. Med.</i> 309(15):883-7 (1983)
	Baum RP et al., "Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma," <i>Cancer</i> 73(3 Suppl):1121-5 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Subt. For, PTO-1449

Docket Number  
107.823.166Application Number  
09/332,866INFORMATION DISCLOSURE  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant  
Leveugle et al.

Filing Date

June 15, 1999

Group Art Unit

1642

RECEIVED

MAR 15 2001

TECH CENTER 1600/2900

	Bernard NF et al., "Possible Role for Specific Surface Immunoglobulin In Antigen Presentation," <i>Antigen Presenting Cells: Diversity, Differentiation, and Regulation</i> 291-300 (1988)
	Boon T et al., "Tumor antigens recognized by T lymphocytes," <i>Annu Rev Immunol.</i> 12:337-65 (1994)
	Brakenhoff RH et al., "Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer," <i>Cancer Immunol Immunother.</i> 40(3):191-200 (1995)
	Bretscher PA et al., "Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to <i>Leishmania major</i> ," <i>Science</i> 257(5069):539-42 (1992)
	Brockmeyer NH et al., "Immunomodulation of cimetidine in healthy volunteers," <i>Klin Wochenschr.</i> 67(1):26-30 (1989)
	Bouige P et al., "Immune complexes as immunizing agents to increase the number of monoclonal antibody producing hybrids and to deviate the response to poorly immunogenic epitopes," <i>Hybridoma</i> 9(6):519-26 (1990)
	Bukowski RM et al., "Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies," <i>J Immunother.</i> 10(6):432-9 (1991)
	Canevari S et al., "Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody," <i>J Natl Cancer Inst.</i> 87(19):1463-9 (1995)
	Chang CT et al., "Circular dichroic analysis of protein conformation: inclusion of the beta-turns," <i>Anal Biochem.</i> 91(1):13-31 (1978)
	Chatterjee MB et al., "Idiotype antibody immunotherapy of cancer," <i>Cancer Immunol Immunother.</i> 38(2):75-82 (1994)
	Chester SJ et al., "Improved detection of the early stages of colon cancer by determining both free circulating and immune complex-bound antigens reactive with monoclonal antibody," <i>Cancer Res.</i> 54(15):3974-8 (1994)
	Cheung NK et al., "Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival," <i>Cancer Res.</i> 54(8):2228-33 (1994)
	Clarke-Pearson DL et al., "Palliative surgery for epithelial ovarian cancer," In Rub SC, Sutton GP eds. <i>Ovarian Cancer</i> New York: McGraw-Hill, Inc. 1993: 351-364
	Crum ED, "Effect of cisplatin upon expression of in vivo immune tumor resistance," <i>Cancer Immunol Immunother.</i> 36(1):18-24 (1993)
	Defoin A et al., "A new liquid phase actinometer: Quantum yield and photo-cidnp study of phenylglyoxylic acid in aqueous solution," <i>J. Photochem.</i> 33:237-255 (1985)
	DiLeo AJ et al., "High resolution removal of virus from protein solutions using a membrane of unique structure," <i>Biotechnology</i> 10(2):182-8 (1992)
	DiLeo AJ et al., "Size exclusion removal of model mammalian viruses using a unique membrane system, Part II: Module qualification and process simulation," <i>Biologicals</i> 21(3):287-96 (1993)
	DiLeo AJ et al., "Size exclusion removal of model mammalian viruses using a unique membrane system, Part I: Membrane qualification," <i>Biologicals</i> 21(3):275-86 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.




Subt. For, PTO-1449				Docket Number 107.823.166		Application Number 09/332,866	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Leveugle et al.			
				Filing Date June 15, 1999		Group Art Unit 1642	
Sheet	3	OF	8				

	Dorai, H et al., "Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function," <i>Hybridoma</i> 10:211-7 (1991)
	Dohlsten M et al., "Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy," <i>Proc Natl Acad Sci U S A.</i> 91(19):8945-9 (1994)
	Dohlsten M et al., "Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo," <i>Proc Natl Acad Sci U S A.</i> 92(21):9791-5 (1995)
	Donnerstag B et al., "Immunological profile of patients with ovarian cancer under immunostimulation with murine monoclonal antibodies," <i>International J. of Oncology</i> 6:853-858 (1995)
	Durrant LG et al., "Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7," <i>Cancer Res.</i> 54(18):4837-40 (1994)
	Ehrke MJ et al., "Effects of anticancer drugs on the immune system in humans," <i>Semin Oncol.</i> 16(3):230-5 (1989)
	Engvall E and Perlman P, "Enzyme-linked immunosorbent assay (ELISA), Quantitative assay of immunoglobulin G," <i>Immunochemistry</i> 8:871 (1971)
	Fagerberg J et al., "Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?," <i>Cancer Immunol Immunother.</i> 37(4):264-70 (1993)
	Fagerberg J et al., "Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotypic reactive T cells (T3) of importance for tumor response to mAb therapy?," <i>Cancer Immunol Immunother.</i> 38(3):149-59 (1994)
	Fagerberg J et al., "Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotypic-reactive T lymphocytes," <i>Cancer Res.</i> 55(9):1824-7 (1995)
	Fendrick JL et al., "Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line," <i>Tumour Biol.</i> 14(5):310-8 (1993)
	Gadducci A et al., "Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study," <i>Gynecol Oncol.</i> 58(1):42-7 (1995)
	Gallagher G and Al-Azzawi F, "Adoptive immunotherapy of experimental ovarian cancer using activated human monocytes and the human monoclonal antibody, anti-14C1," <i>Intl J of Oncology</i> 5:253-258 (1994)
	Gallagher G et al., "Multiple epitopes of the human ovarian cancer antigen 14C1 recognised by human IgG antibodies: their potential in immunotherapy," <i>Br J Cancer</i> 64(1):35-40 (1991)
	Geffner JR et al., "Activation of human neutrophils and monocytes induced by immune complexes prepared with cationized antibodies or antigens," <i>Clin Immunol Immunopathol.</i> 69(1):9-15 (1993)
	Goldenberg DM "New developments in monoclonal antibodies for cancer detection and therapy," <i>CA Cancer J Clin.</i> 44(1):43-64 (1994)
	Goronzy J et al., "Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4," <i>J Exp Med.</i> 164(3):911-25 (1986)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	





Subt. For, PTO-1449

# INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Sheet	4	OF	8
-------	---	----	---

Docket Number  
107.823.166

Application Number  
09/332,866

Applicant  
Leveugle et al.

Filing Date  
June 15, 1999


Group Art Unit  
1642

	Handgretinger R et al., "A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma," <i>Eur J Cancer</i> . 31A(2):261-7 (1995)
	Hariharan K et al., "The induction of cytotoxic T cells and tumor regression by soluble antigen formulation," <i>Cancer Res</i> . 55(16):3486-9 (1995)
	Harris JE and Braun DP, "Abnormal Immunoregulation and the tumor dormant state in human cancer," In: Stewart THM, Wheelock eds. Cellular immune mechanisms and tumor dormancy, Boca Raton, Florida: CRC Press 261-276 (1992)
	Hoskins PJ et al., "Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy," <i>J Clin Oncol</i> . 10(10):1561-8 (1992)
	Hozumi N and Sandhu JS, "Recombinant antibody technology: its advent and advances," <i>Cancer Invest</i> . 11(6):714-23 (1993)
	Hayat MA, <u>Colloidal Gold: Principles, Methods, and Applications</u> Vol. 1, San Diego: Academic Press, Inc. 1989
	Ioannides CG et al., "Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides," <i>J Immunol</i> . 151(7):3693-703 (1993)
	Jacoby RO et al., "Characterization of mouse parvovirus infection by in situ hybridization," <i>J Virol</i> . 69(6):3915-9 (1995)
	Jensen JL et al., "Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management," <i>Int. J. Biol. Markers</i> 6:1 (1991)
	Jerne NK, "Towards a network theory of the immune system," <i>Ann Immunol (Paris)</i> 125C(1-2):373-89 (1974)
	Kehoe S, "Cell-mediated immunity and immunotherapy in ovarian cancer (review)," <i>Intl J of Oncology</i> 6:451-458 (1995)
	Khazaeli MB et al., "Human immune response to monoclonal antibodies," <i>J Immunother</i> . 15(1):42-52 (1994)
	Kim HT et al., "Gamma delta T cell recognition of tumor Ig peptide," <i>J Immunol</i> . 154(4):1614-23 (1995)
	Knuth A et al., "T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures," <i>Proc Natl Acad Sci U S A</i> 81(11):3511-5 (1984)
	Kobayashi H et al., "Characterization of CA 125 antigen identified by monoclonal antibodies that recognize different epitopes," <i>Clin Biochem</i> . 26(5):391-7 (1993)
	Kosmas C et al., "Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer," <i>Cancer</i> 73(12):3000-10 (1994)
	Kosmas C et al., "Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens," <i>Br J Cancer</i> 64(3):494-500 (1991)
	FT Kreutz and Suresh MR, "Biospecific monoclonal Anti-CA125 X Anti-peroxidase antibodies in the measurement of the ovarian carcinoma antigen," <i>J of Tumor Marker Oncology</i> 10(1): 45-53 (1995)
	Lamers CH et al., "Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytotoxicity by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes," <i>Int J Cancer</i> 60(4):450-7 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Subt. For, PTO-1449

INFORMATION DISCLOSURE  
IN AN APPLICATION

(Use several sheets if necessary)

Sheet

5

OF

8


Docket Number  
107.823.166Application Number  
09/332,866Applicant  
Leveugle et al.Filing Date  
June 15, 1999Group Art Unit  
1642

	Lanzavecchia A, "Identifying strategies for immune intervention," <i>Science</i> 260(5110):937-44 (1993)
	Lanzavecchia A et al., "Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets," <i>J Exp Med.</i> 167(2):345-52 (1988)
	Livingston Po et al., "Symposium 10: glucosylation defining malignancy. Effect of active immunization with human tumor associated carbohydrate antigens on the immune response and on tumor growth," <i>Proc. Am. Assoc. Cancer Research</i> 36:678 (1995)
	Loevinger, RL et al., <i>MIRD Primer for Absorbed Dose Calculations</i> New York: Society of Nuclear Medicine, 1991
	Lopes LM and Chain BM, "Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen," <i>Eur J Immunol.</i> 22(1):287-90 (1992)
	Madiyalakan R et al., "Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13," <i>Hybridoma</i> 14(2):199-203 (1995)
	Manca F et al., "Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies," <i>J Exp Med.</i> 173(1):37-48 (1991)
	Maraveyas A and Epenetos AA, "Targeted immunotherapy. An update with special emphasis on ovarian cancer," <i>Acta Oncol.</i> 32(7-8):741-6 (1993)
	Martin AC et al., "Modeling antibody hypervariable loops: a combined algorithm," <i>Proc Natl Acad Sci U S A</i> 86:9268-72 (1986)
	Marusic-Galesic S et al., "Cellular immune response to the antigen administered as an immune complex," <i>Immunology.</i> 72(4):526-31 (1991)
	Meier W, "CA 125 based diagnosis and therapy in recurrent ovarian cancer," Abstract. <i>Abstracts of the Eighth International Hamburg Symposium on Tumor Markers</i> Hamburg, Germany 2443 (1995)
	Mitchell MS, <i>Biological Approaches to Cancer Treatment: Biomodulation</i> New York: McGrawHill, Inc., 1993
	Mitchell MS et al., "Biomodulators in cancer treatment," <i>J Clin Pharmacol.</i> 32(1):2-9 (1992)
	Mosmann TR and RL Coffman, "Two types of mouse helper t-cell clone, Review. <i>Immunology Today</i> 8(7 and 8):223-227 (1987)
	Muddukrishna SN et al., "Indirect iodometric procedure for quantation of Sn(II) in radiopharmaceutical kits," <i>Appl. Radial. Isot.</i> 45(3):293-299 (1994)
	Munn DH and Cheung NK "Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma," <i>Cancer Res.</i> 47(24 Pt 1):6600-5 (1987)
	Naramura M et al., "Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma," <i>Cancer Immunol Immunother.</i> 37(5):343-9 (1993)
	National Cancer Institute of Canada, "Canadian Cancer Statistics" Toronto: National Cancer Institute of Canada (1998)
	Nemazee DA and Sato VL, "Enhancing antibody: a novel component of the immune response," <i>Proc Natl Acad Sci U S A.</i> 79(12):3828-32 (1982)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Subt. For, PTO-1449

INFORMATION DISCLOSURE  
IN AN APPLICATION

(Use several sheets if necessary)


Docket Number  
107.823.166Application Number  
09/332,866Applicant  
Leveugle et al.Filing Date  
June 15, 1999Group Art Unit  
1642

	Ohta S et al., "Tumor-associated glycoantigen, sialyl Lewis <sup>a</sup> as a target for bispecific antibody-directed adoptive tumor immunotherapy," <i>Immunol Lett.</i> 44(1):35-40 (1995)
	Ovarian Cancer: Screening, Treatment, and Followup. NIH Consens Statement 12(3):1-30 (1994)
	Ozols, MD, PhD, RF "Biologic Treatment of Human Cancer," <i>Current Problems in Cancer</i> 19(4):186-261 (1995)
	Pederson J et al., "Antibody Modeling: Beyond Homology," <i>Immunomethods</i> 1:126-136 (1992)
	Perala-Heape M et al., "Effects of tumour mass and circulating antigen on the biodistribution of <sup>111</sup> In-labelled F(ab') <sub>2</sub> fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts," <i>Eur J Nucl Med.</i> 18(5):339-45 (1991)
	Pierce SK and LA Casten, "Soluble globular protein antigens covalently coupled to antibodies specific for b cell surface structures are effective antigens both in vitro and in vivo," <i>Antigen presenting cells: diversity, differentiation, and regulation</i> 259-268 (1988)
	Pimm MV, "Circulating antigen: bad or good for immunoscintigraphy?" <i>Nucl Med Biol.</i> 22(2):137-45. Review. (1995)
	Pimm MV et al., "Influence of syngeneic monoclonal anti-idiotypic antibodies to murine monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments," <i>J Cancer Res Clin Oncol.</i> 119(7):408-14 (1993)
	Pimm MV and Gribben SJ, "Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice," <i>J Cancer Res Clin Oncol.</i> 119(1):41-5 (1992)
	Provencher SW and Glockner J, "Estimation of globular protein secondary structure from circular dichroism," <i>Biochemistry</i> 20(1):33-7 (1981)
	Randall RE et al., "Purification of antibody-antigen complexes containing recombinant SIV proteins: comparison of antigen and antibody-antigen complexes for immune priming," <i>Vaccine</i> 12(4):351-8 (1994)
	Riethmuller G et al., "Monoclonal antibodies in cancer therapy," <i>Curr Opin Immunol.</i> 5(5):732-9 (1993)
	Riethmuller G et al., "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <i>Lancet</i> 343(8907):1177-83 (1994)
	Ron IG et al., "Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma," <i>Acta Obstet Gynecol Scand.</i> 73(8):658-62 (1994)
	Roosnek E and A Lanzavecchia, "Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells," <i>J Exp Med.</i> 173(2):487-9 (1991)
	Schlebusch H et al., "A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer," <i>Hybridoma</i> 14(2):167-7 (1995)
	Schmolling J et al., "Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3," <i>Hybridoma</i> 14(2):183-6 (1995)

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Subt. For, PTO-1449				Docket Number 107.823.166		Application Number 09/332,866	
INFORMATION DISCLOSURE IN AN APPLICATION  (Use several sheets if necessary)				Applicant Leveugle et al.			
				Filing Date June 15, 1999		Group Art Unit 1642	
Sheet	7	OF	8				

	Schultes BC et al., "Idiotypic cascades after injection of the monoclonal antibody OC125: a study in a mouse model. Induction of antibodies against OC125 and CA125 after immunization with an anti-CA 125 (MAb OC125) monoclonal antibody by activation of the idiotypic network," <i>Eur J Clin Chem Clin Biochem.</i> 31(7):427-32 (1993)
	Sciammas R et al., "TCR gamma delta cells: mysterious cells of the immune system," <i>Immunol Res.</i> 13(4):268-79 (1994)
	Shitara K et al., "A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities," <i>Cancer Immunol Immunother.</i> 36(6):373-80 (1993)
	Snyder et al., <u>A Tabulation of Dose Equivalent per Microurie-Day for Source and Target Organs of an Adult for Various Radionuclides</u> Oak Ridge National Laboratory, Oak Ridge Tn (1975)
	Spalding BJ, "Few firms pursue anti-ids," <i>Bio/Technology</i> 10:950 (1992)
	Squire CM et al., "Antigen presentation is enhanced by targeting antigen to the Fc epsilon RII by antigen-anti-Fc epsilon RII conjugates," <i>J Immunol.</i> 152(9):4388-96 (1994)
	Stevenson FK and RE Hawkins, "Molecular Vaccines Against Cancer," <i>Immunologist</i> 2(1):16-19 (1994)
	Strieter RM et al., "Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline," <i>Biochem Biophys Res Commun.</i> 155(3):1230-6 (1988)
	Sulica A et al., "Regulation of human natural cytotoxicity by IgG. IV. Association between binding of monomeric IgG to the Fc receptors on large granular lymphocytes and inhibition of natural killer (NK) cell activity," <i>Cell Immunol.</i> 147(2):397-410 (1993)
	Taggart, RT, Samloff IM., "Stable antibody-producing murine hybridomas," <i>Science</i> 219:1228-1230 (1983)
	Tew JG et al., "Induction of the secondary antibody response: immune complex formation, iccosome release by follicular dendritic cells, processing and presentation of antigen by germinal center b cells and tingible body macrophages," <i>Progress in Leukocyte Biology</i> 7:1-10 Alan R Liss, Inc., New York (1988)
	Thomson AW and JV Forrester, "Therapeutic advances in immunosuppression," <i>Clin Exp Immunol.</i> 98(3):351-7 (1994)
	Torbett BE et al., "hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis," <i>Immunol Rev.</i> 124:139-64 (1991)
	Trauth BC et al., "Monoclonal antibody-mediated tumor regression by induction of apoptosis," <i>Science</i> 245(4915):301-5 (1989)
	Ullman EF et al., "Anti-immune complex antibodies enhance affinity and specificity of primary antibodies," <i>Proc Natl Acad Sci U S A.</i> 90(4):1184-9 (1993)
	United Nations, Demographic Yearbook, 1992 Forty-fourth issue, New York (1994)
	United Nations Population Fund, The State of World Population, 1991
	van der Bruggen P, "The long-standing quest for tumor rejection antigens," <i>Clin Immunol Immunopathol</i> 71(3):248-52 (1994)
	Vitetta ES and JW Uhr, "Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy," <i>Cancer Res.</i> 54(20):5301-9 (1994)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	



Subt. For, PTO-1449				Docket Number 107.823.166		Application Number 09/332,866	
INFORMATION DISCLOSURE IN AN APPLICATION  (Use several sheets if necessary)				Applicant Leveugle et al.			
				Filing Date June 15, 1999		Group Art Unit 1642	
Sheet	8	OF	8				

	Vose BM and Bonnard GD, "Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2," <i>Int J Cancer</i> 29(1):33-9 (1982)
	Wagner U, "Antitumor antibodies for immunotherapy of ovarian carcinomas," <i>Hybridoma</i> 12(5):521-8 (1993)
	Wagner U et al., "Clinical courses of patients with ovarian carcinomas after induction of anti-idiotypic antibodies against a tumor-associated antigen," <i>Tumor Diagnostic &amp; Therapic</i> 11:1-4 (1990)
	Wagner UA et al., "Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network," <i>Biotechnol Ther.</i> 3(1-2):81-9 (1992)
	Walker AM et al., "Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes," <i>Proc Natl Acad Sci U S A.</i> 92(8):3278-82 (1995)
	Wawrzynczak EJ et al., "Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains," <i>Mol Immunol.</i> 29:213-20 (1992)
	Weber D, <i>MIRD: Radiocluclide Data and Decay Schemes</i> New York: Society of Nuclear Medicine, 1989
	Wiersma EJ et al., "Enhancement of the antibody response to protein antigens by specific IgG under different experimental conditions," <i>Scand J Immunol.</i> 36(2):193-200 (1992)
	Wolff EA et al., "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice," <i>Cancer Res.</i> 53(11):2560-5 (1993)
	Wyatt, PJ "Light scattering and the absolute characterization of macromolecules" Review. <i>Analytica Chimica Acta</i> 272:1-40 (1993)
	Xu ZY et al., "Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin," <i>Cancer Res.</i> 48(23):6658-63 (1988)
	Yano S et al., "Natural antibodies against the immunoglobulin F(ab')2 fragment cause elimination of antigens recognized by the F(ab')2 from the circulation," <i>Eur J Immunol.</i> 25(11):3128-33 (1995)
	Zhang S et al., "Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides," <i>Cancer Immunol Immunother.</i> 40(2):88-94 (1995)

diana havens - h:\chiu\_nancy\legal\docs\altarex\107823.166\altarexids 166.doc

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	